Specialty ingredients made bioavailable by design method — not by a new particle
An AI-first platform that designs each carrier to fit its molecule — against the conditions that change along the absorption path, across a defined class of high-value bioactives. We protect the method, not the molecule.
The bioactive layer is crowded. Premium bioavailability is decided by how the carrier is designed — not by the molecule.
Whether a bioactive survives, is absorbed, and acts is decided by how its carrier is designed. We fit that design per molecule — with an AI method that holds across a defined class of high-value bioactives.
Better delivery is not an end in itself. If a molecule arrives intact and in dose, less of it is needed for the same exposure — which is where tolerability, cost and formulation freedom can start to move.
An AI design method that fits a carrier to each molecule, across a defined class of high-value bioactives.
A carrier designed per molecule against the conditions that change along the absorption path. Science-led, AI-operated, human-governed — every output verified and owned by people, across the venture lifecycle.
Premium-bioavailable longevity ingredients form the fastest-growing slice of a healthspan market that is increasingly priced and validated on pharma terms.
The first commercial application is specialty ingredients. The method itself is not category-bound — what changes across categories is the proof threshold, not the approach.
Cellular health drives longevity. Most ingredients never get there.
Inflammation and cellular health are the operational layer of longevity outcomes. Yet most premium supplements fail at the simplest test — they never reach the cells they were designed to act on.
Inflammation and cellular function drive the outcomes longevity-buyers actually pay for. The category has matured beyond generic antioxidants — premium brands now compete on mechanism, not marketing.
An entire class of high-value bioactives has remained effectively inaccessible at oral scale — molecules well-documented in cellular and inflammatory assays for decades, with no viable uptake pathway in the human body. The science is ready. Getting it into the body is not.
AI-first venture-building has reached operational maturity. Rapid iteration on carrier-architecture is no longer the multi-year cycle it used to be. The work is science-led, AI-operated, and human-governed — every result verified and owned by people, which makes this practical for the first time.
The category, the bioactives, the operating method — all arrive simultaneously. That is the timing thesis.